Spyre Therapeutics, Inc. (3920)
FSX
Closed
Aug 25, 2026
Day's Range
90.5052 wk Range
12.30Overview - 3920 - Spyre Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
5.90B
P/E (Trailing)
‪3.23‬
PEG Ratio
‪-0.10‬
Price / Book
‪9.64‬
EV / EBITDA
‪-25.71‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-19.81%‬
Return on Equity
‪-22.98%‬
Ownership
Shares Outstanding
88.06M
Float
82.14M
Held by Insiders
‪5.73%‬
Held by Institutions
‪110.68%‬
Price stats
Beta
‪3.02‬
50-Day Avg
‪83.75‬
200-Day Avg
‪50.92‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 3920 - Spyre Therapeutics, Inc.
Peers - 3920 - Spyre Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 3920FSXSpyre Therapeutics, Inc.8.06BMarket Cap+84.04%52-week change3.24P/E (Trailing)‪0.00%‬Profit Margin
- ANLFSXAnalog Devices, Inc.152.94BMarket Cap+29.62%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- 1AEFSXargenx SE56.27BMarket Cap+30.57%52-week change39.07P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt54.72BMarket Cap+33.14%52-week change39.13P/E (Trailing)‪32.26%‬Profit Margin
- 0QFFSXModerna, Inc.47.69BMarket Cap+84.54%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 42ZFSXRevolution Medicines Inc.37.93BMarket Cap+83.17%52-week change-30.35P/E (Trailing)‪0.00%‬Profit Margin
- 49BAFSXBeOne Medicines, Ltd. American Depositary Receipt35.29BMarket Cap+16.03%52-week change65.41P/E (Trailing)‪10.69%‬Profit Margin
Profile Summary - 3920 - Spyre Therapeutics, Inc.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD)…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
